Celldex Therapeutics Balance Sheet
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Celldex Therapeutics financial position
At the end of fiscal 2025, Celldex Therapeutics reported total assets of $583.0 million, down 26.4% from a year earlier against total liabilities of $55.8 million. Shareholders' equity stood at $527.2 million, or 90.4% of assets. The company held $28.9 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.49, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Celldex Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 28.87M | 28.36M | 34.81M | 29.43M | 39.14M | 43.84M | 11.23M | 24.31M | 40.29M | 42.46M |
| Short-Term Investments | 489.70M | 696.92M | 388.78M | 275.52M | 369.11M | 150.59M | 53.15M | 69.71M | 99.14M | 147.31M |
| Total Current Assets | 534.66M | 747.16M | 431.69M | 317.69M | 410.84M | 197.84M | 66.70M | 99.08M | 144.76M | 195.57M |
| Property, Plant & Equipment | 5.33M | 4.35M | 4.06M | 3.75M | 3.55M | 3.81M | 4.03M | 6.11M | 10.37M | 13.19M |
| Goodwill | — | — | — | — | — | — | — | — | 90.98M | 90.98M |
| Intangible Assets | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 30.69M | 48.69M | 48.69M | 67.59M | 81.49M |
| Total Assets | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M | 235.84M | 122.93M | 155.81M | 315.62M | 383.36M |
| Accounts Payable | 1.18M | 3.27M | 3.49M | 3.34M | 1.23M | 1.05M | 1.17M | 1.07M | 1.72M | 1.74M |
| Total Current Liabilities | 50.99M | 39.50M | 31.13M | 18.61M | 16.53M | 14.21M | 11.64M | 12.60M | 27.74M | 35.22M |
| Total Liabilities | 55.82M | 45.34M | 36.46M | 26.53M | 25.18M | 26.48M | 28.91M | 31.75M | 79.25M | 117.93M |
| Shareholders' Equity | 527.16M | 747.00M | 429.17M | 326.20M | 419.48M | 209.36M | 94.03M | 124.06M | 236.37M | 265.43M |
| Retained Earnings | -1.81B | -1.56B | -1.40B | -1.26B | -1.14B | -1.07B | -1.01B | -962.44M | -812.52M | -719.49M |
| Net Cash (Debt) | 518.57M | 725.28M | 423.60M | 304.95M | 408.25M | 194.42M | 64.38M | 94.02M | 139.43M | 189.78M |
| Shares Outstanding | 66.55M | 66.37M | 55.88M | 47.20M | 46.73M | 39.60M | 16.97M | 11.96M | 9.23M | 120.52M |
This table shows 10 annual periods of Celldex Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow CLDX's reporting calendar. What is a balance sheet?